Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High complete response rate seen with novel CAR-T for myeloma

Key clinical point: A chimeric antigen receptor construct targeting BCMA induced a high complete response rate in patients with heavily pretreated multiple myeloma.

Major finding: The overall response rate was 100%.

Study details: Phase 1b/2 trial in patients with multiple myeloma relapsed or refractory to at least 3 prior lines of therapy.

Disclosures: The CARTITUDE-1 trial is funded by Janssen Research & Development. Dr. Madduri disclosed serving as a consultant to Janssen and to Takeda, Foundation Medicine, AbbVie, and Celgene.


Madduri D et al. ASH 2019. Abstract 577.